|Description||ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.|
CEP-14083 is a ALK inhibitor. It has a potent activity against ALK in enzymatic assays (IC50 = 11 nmol/L). CEP-14083 can also inhibit the insulin receptor at a ...
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less pote...
CEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with po...
LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapi...
AP26113 is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with pote...
IN-1130 is a selective ALK5 inhibitor with >100 fold selectivity over p38α and a panel of 26 other serine/threonine and tyrosine kinases. It also inhibit phosph...
CEP-14513 is a ALK inhibitor. It shows ALK inhibitory activity in both in vitro enzymatic assay (IC50 = 5 nM) and cell-based assays of ALK tyrosine phosphorylat...
CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity.
Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing ...
CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers...
K02288 is a highly selective 2-aminopyridinebased inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current le...
DMH-1 is a second-generation small molecule BMP inhibitor based on dorsomorphin. DMH-1 effectively inhibits the bone morphogenic protein (BMP) ALK2 receptor (IC...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-ki...
ALK inhibitor 2
ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2. LDN-212854 exhibits some selectivity for ALK2 in preference to other...
Brigatinib, is an orally active, also known as AP-26113, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase(ALK belongs to t...
This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The I...
LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.